Global Anti-VEGF Therapies Market Growth (Status and Outlook) 2024-2030

Global Anti-VEGF Therapies Market Growth (Status and Outlook) 2024-2030

Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.

The global Anti-VEGF Therapies market size is projected to grow from US$ 891 million in 2024 to US$ 1303 million in 2030; it is expected to grow at a CAGR of 6.5% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Anti-VEGF Therapies Industry Forecast” looks at past sales and reviews total world Anti-VEGF Therapies sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Therapies sales for 2023 through 2029. With Anti-VEGF Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Therapies industry.

This Insight Report provides a comprehensive analysis of the global Anti-VEGF Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Anti-VEGF Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Therapies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Therapies.

United States market for Anti-VEGF Therapies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Anti-VEGF Therapies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Anti-VEGF Therapies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Anti-VEGF Therapies players cover Roche, Eli Lilly, Pfizer, Regeneron Pharmaceuticals, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Therapies market by product type, application, key players and key regions and countries.

Segmentation by Type:
Bevacizumab
Ramucirumab
Ranibizumab
Aflibercept
Conbercept
Other

Segmentation by Application:
Hospitals
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Bevacizumab
Ramucirumab
Ranibizumab
Aflibercept
Conbercept
Other

Segmentation by Application:
Hospitals
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Eli Lilly
Pfizer
Regeneron Pharmaceuticals
Novartis
Alphamab Oncology
Chengdu Kanghong Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.